<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oxidized <z:chebi fb="15" ids="39026">LDL</z:chebi> (oxLDL) is a key mediator in atherogenesis and a marker of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) </plain></SENT>
<SENT sid="1" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with excessive <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Because atherogenesis starts before <z:mp ids='MP_0002055'>diabetes</z:mp> is diagnosed, we investigated whether circulating oxLDL levels are increased in <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) </plain></SENT>
<SENT sid="3" pm="."><plain>OxLDL levels were measured in 376 subjects with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT), 113 patients with IGT, and 54 patients with newly diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>After correction for age and BMI, serum levels of oxLDL were significantly increased in IGT versus NGT subjects (P = 0.002) </plain></SENT>
<SENT sid="5" pm="."><plain>OxLDL levels were not associated with the following parameters of the oxidative/antioxidative balance in the blood: total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity, urate-to-<z:chebi fb="0" ids="15676">allantoin</z:chebi> ratio, and circulating phagocyte oxygenation activity </plain></SENT>
<SENT sid="6" pm="."><plain>In stepwise multivariate analysis, <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (P &lt; 0.0005) and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (P &lt; 0.0005) were the strongest predictors of circulating oxLDL levels, followed by <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (P = 0.003), 2-h postchallenge C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (P = 0.011), fasting free fatty acids (P = 0.013), and serum paraoxonase activity (P = 0.035) </plain></SENT>
<SENT sid="7" pm="."><plain>The strong correlation of oxLDL with <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> indicates that <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation in IGT is preferentially associated with <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>OxLDL increase may explain the high atherogenic potency of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic state</z:e> </plain></SENT>
</text></document>